Mendelspod Podcast-logo

Mendelspod Podcast

Science Podcasts >

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.
More Information

Location:

United States

Description:

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

Language:

English


Episodes

Why Isn’t Personalized Medicine Being Mentioned by the Presidential Contenders? Ed Abrahams on Drug Pricing, Genetic Testing, and the State of the Industry in 2019

10/15/2019
More
Ed Abrahams has a message for Nancy Pelosi about HR 3. That’s the new bill in the House to reduce drug pricing. Ed is the President of the Personalized Medicine Coalition, an advocacy organization in Washington representing our industry which will soon announce a new caucus in congress devoted to personalized medicine. Ed joins us today and says to Pelosi, there’s a better way, a more American way to reduce drug costs.

Duration:00:36:22

Karen Miga on the Next Era of Genomics

10/7/2019
More
"Welcome to the era of T2T genomics,” tweeted UCSC’s Karen Miga on August 16th of this year. Then she linked to a paper on bioRxiv that begins: "After nearly two decades of improvements, the current human reference genome (GRCh38) is the most accurate and complete vertebrate genome ever produced. However, no one chromosome has been finished end to end, and hundreds of unresolved gaps persist.”

Duration:00:25:49

September 2019 Review with Nathan and Laura: Same-Sex Genetics, Mosquitos, and Another DTC Scandal

9/30/2019
More
After the summer break, Nathan and Laura, stir from their beach slumbers, to again offer their anything but sleepy opinions on the latest genomics headlines.

Duration:00:56:54

We Can See Tumor Heterogeneity. Now What? We Ask Cathy Smith, UCSF

9/17/2019
More
Cathy Smith counts herself among the Gleevec Generation after the landmark targeted cancer therapy. She’s an optimist who believes in the possibilities of precision medicine. “We are outsmarting cancer,” she says. Cathy is an Assistant Professor of Hematology/Oncology at UCSF where she is also an MD treating patients. Her area of expertise is in acute myeloid leukemia or AML. She joins us today to discuss a recent group paper and collaboration using new technology to track and monitor cancer...

Duration:00:29:39

Hallelujah! A Universal Flu Preventative and Therapy with Jeff Stein, Cidara

9/12/2019
More
As another summer winds down, another flu season approaches. Yuuuk. When will we be able to stop living in fear of that crowded plane flight in winter months or waking up congested and wondering . . . dreading, “am I coming down with a cold?” Yes, we get that annual flu vaccine shot, but each year we still get the bug. Until now, a real universal flu vaccine has eluded drug makers, and having the flu goes on being just part of life. But it doesn't have to be.

Duration:00:23:13

'The Movement:' John Cumbers Previews the Rapidly Growing SynBioBeta 2019

9/2/2019
More
Synthetic biology is experiencing a second renaissance and the place to be this October 1-3 is at the SynBioBeta conference in San Francisco. For those of you who are going, today’s show is your preview. For those of you who need a nudge, just listen to what conference founder, John Cumbers, has conjured up in this biggest and most diverse lineup yet.

Duration:00:40:10

Anya Prince on Our Current Vulnerability to Genetic Discrimination

8/13/2019
More
Some Americans still resist genetic testing for fear they will be discriminated against by insurance companies. Why? in 2008, Congress passed GINA, the Genetic Information Nondiscrimination Act, to protect us from insurance companies choosing to include us or not for policies based on the genes we came with. Then in 2010, Congress passed the ACA, or Affordable Care Act, and with it protection against preexisting conditions. This includes genetic predispositions.

Duration:00:29:22

Do Long Reads Hold Answers for Alzheimer’s? with Mark Ebbert, Mayo

7/31/2019
More
It’s the kind of plot that makes great science. There are genes that have been hiding in plain sight, undetected until now. They’ve gone unseen, that is, by short read sequencing. Today’s guest and his colleagues call them “camouflage genes,” and a couple in particular may play functional roles in Alzheimer’s disease. Mark Ebbert is an Assistant Professor of Neuroscience at the Mayo Clinic where he is using long read sequencing technology and computational biology to study neurodegenerative...

Duration:00:32:13

With Nanopore Sensing Beyond Sequencing, Ontera Takes 'Lab' to the Field

7/25/2019
More
We’ve interviewed several CEOs over the years since the Theranos fiasco who avoided any mention of the blighted company whenever the comparison came up. But today’s guest, Murielle Thinard McLane, the CEO of Ontera, jumped at the chance before Theral could get to it. "Some people might say, well that's the Theranos model. They (Theranos) didn't get it wrong. The demand for a fast, comprehensive point-of-care solution near the patient is there. Where they got it wrong is that you need a...

Duration:00:25:04

Mark Chaisson on Two New Structural Variation Papers

7/17/2019
More
If you’re not on the long read sequencing train, you’re not landing in the world of genomics. A new paper out begins, "Structural variants contribute greater diversity at the nucleotide level between two human genomes than another form of genetic variation.”

Duration:00:41:30

Early Cancer Detection: Is This Company Ahead of Grail?

7/8/2019
More
The great promise of liquid biopsy technology is in early cancer detection. That is, it's the great future promise. Right? This past month at the annual cancer conference, ASCO, we heard about one such flagship company announcing just which technology they were going to use to do it--DNA methylation.

Duration:00:31:59

June 2019 Review with Nathan and Laura: Gene Patents, Grail, Dr. Lynch

6/30/2019
More
Nathan and Laura join Theral for our final review show before the summer break. Have you already headed out on vacation? Take us along and stay current with the top stories in genomics. This month it's gene patents (yes, Congress is really reviving that debate), another gene therapy with another astronomical price tag, and remembering Dr. Henry Lynch of Lynch Syndrome fame.

Duration:00:42:49

Should Genomic Screening Be Standard of Care? with Adam Buchanan, Geisinger

6/25/2019
More
Those of us watching every shift in the level of adoption of genomic medicine have our eyes closely glued to Geisinger Health System in Pennsylvania. Adam Buchanan is the Co-Director of Geisinger’s MyCode Genomic Screening and Counseling program, and today we talk to him about the rationale of making genomic screening part of routine medical care.

Duration:00:37:42

May 2019 Review with Nathan and Laura: Gene Therapies, DTC Shifts, Gender and Sports

5/31/2019
More
Our two reigning champions are back for a month packed with news. It’s Nathan Pearson of Root and Laura Hercher of Sarah Laurence College and Host of The Beagle Has Landed Podcast daring to go where no genomics commentators have gone before.

Duration:00:51:46

Toward the Human Pan Genome with Adam Phillippy, NHGRI

5/23/2019
More
Storylines repeat in genome science every decade or so. The human genome is complete. No. Now it's complete. Or, in the 90's, it was first announced that the first chromosome was sequenced. We have the same story for you today--breaking news from a paper that has not even been published yet: the first “complete” assembly of a human chromosome, end to end, telomere to telomere. So what’s going on?

Duration:00:35:11

Laura Hercher on the DTC Genetic Testing Landscape

5/16/2019
More
"DTC is now too big of an arena to put everything in the same bucket.” This was a line from Laura Hercher, one of our monthly commentators a couple shows back. The statement made its way around Twitter, so we thought we’d have Laura back to the program and ask her to come up with some more buckets. It turns out it’s not that easy. Direct-to-consumer genetic testing is a dynamic and complex space in 2019, a mishmash that quite defies easy categorization.

Duration:00:49:14

Arcadia Biosciences Pivots to Bring Us Non-GMO, High Fiber GoodWheat and Better Cannabis

5/9/2019
More
Today we're joined by Matt Plavan, President of Arcadia Specialty Genomics. The last time we talked with someone from Arcadia Bioscience, a biotech company working on plant genomics in Davis, California, they were confronting GMO regulatory hurdles. Which was a pity. They had created these great new strains of rice and soybeans, among other crops, that were being held from market due to regulations in Southeast Asia. This at a time when world population is . . . well, you know what its doing.

Duration:00:28:51

April 2019 Review with Nathan and Laura: uBiome Raided by FBI, PRS for Obesity, and a Gene Therapy Cure

5/2/2019
More
April was a tough month for some genomics companies. The FBI raided the offices of uBiome and two other pioneers in the field failed. Are there broader implications? Nathan and Laura have returned to first give us some facts and then to throw their hats in the ring. Lots happened this month in the world of DNA. Tune in and catch it all.

Duration:00:42:30

The Era of the Social Genome with Rodrigo Martinez, Veritas Genetics

4/18/2019
More
Two years ago Veritas Genetics began offering whole genome sequencing for a thousand dollars. It was a significant milestone—and still is!—not only for what it means about the company providing the genomes but also what it means about the demand for such a product.

Duration:00:49:19

Reassessing Alzheimer’s with Larry Goldstein, UCSD

4/8/2019
More
There are drug trial failures. And there are drug trial failures. The recent move by drug giant Biogen to halt their Alzheimer’s drug has not only been a setback for the company—their stock fell precipitously on the news—it’s also been a major setback for the whole research community focused on this disease. The Biogen trial was one of the last of the major drug companies with high hopes for a significant therapeutic step forward for the neurodegenerative disease. The last five years has...

Duration:00:32:59